These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2073819)

  • 21. Effect of phospholipase A2 inhibitors on mouse T lymphocytes. I. Phospholipase A2 inhibitors exert similar immunological activities as glycosylation inhibiting factor.
    Ohno H; Iwata M; Nakamura T; Ishizaka K
    Int Immunol; 1989; 1(4):425-33. PubMed ID: 2535136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of IgE synthesis.
    Ishizaka K
    Annu Rev Immunol; 1984; 2():159-82. PubMed ID: 6085750
    [No Abstract]   [Full Text] [Related]  

  • 23. Expression of low-affinity receptor for IgE (Fc epsilon RII, CD23) and IgE-BF (soluble CD23) release by lymphoblastoid B-cell line RPMI-8866 and human peripheral lymphocytes of normal and atopic donors.
    Bujanowski-Weber J; Brings B; Knöller I; Pfeil T; König W
    Immunology; 1989 Apr; 66(4):505-11. PubMed ID: 2523859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Regulation of c-myc expression by Blimp-1 during the differentiation of myeloma cells].
    Zhou X; Zhou F; Jiang H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):318-22. PubMed ID: 17877160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoglobulin G-binding factors (IgG-BF) inhibit IgG secretion by, as well as proliferation of, hybridoma B cells.
    Teillaud JL; Amigorena S; Moncuit J; Sautès C; Fridman WH
    Immunol Lett; 1987 Nov; 16(2):139-44. PubMed ID: 3501404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Oct-2 in immunoglobulin gene silencing.
    Radomska HS; Hines MD; Eckhardt LA
    Ann N Y Acad Sci; 1995 Sep; 764():148-50. PubMed ID: 7486513
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunopharmacological approach to the modulation of IgE antibody formation].
    Yanagihara Y; Koda A
    Nihon Yakurigaku Zasshi; 1987 Jul; 90(1):1-11. PubMed ID: 3308659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
    Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
    Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated c-myc messenger RNA in multiple myeloma cell lines.
    Fourney R; Palmer M; Ng A; Dietrich K; Belch A; Paterson M; Brox L
    Dis Markers; 1990; 8(3):117-24. PubMed ID: 1980237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the Fc gamma RII-related component of murine IgG-BF.
    Blank U; Daëron M; Galinha A; Malard V; Fridman WH; Sautès C
    Mol Immunol; 1989 Feb; 26(2):107-14. PubMed ID: 2465488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloma expression systems.
    Yoo EM; Chintalacharuvu KR; Penichet ML; Morrison SL
    J Immunol Methods; 2002 Mar; 261(1-2):1-20. PubMed ID: 11861062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.
    Holien T; Våtsveen TK; Hella H; Rampa C; Brede G; Grøseth LA; Rekvig M; Børset M; Standal T; Waage A; Sundan A
    Leukemia; 2012 May; 26(5):1073-80. PubMed ID: 21941367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
    Pope B; Brown R; Luo XF; Gibson J; Joshua D
    Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes.
    Takishita M; Kosaka M
    Leuk Lymphoma; 1995 Nov; 19(5-6):395-400. PubMed ID: 8590838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extinction of expression of the translocated myc gene in somatic cell hybrids between mouse myeloma and L-cells.
    Greenberg A; Hijazzi M; Sharir H; Cohen L; Bergman Y; Ber R; Laskov R
    Int J Cancer; 1989 Jan; 43(1):87-92. PubMed ID: 2492015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD11b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients.
    Jensen GS; Belch AR; Kherani F; Mant MJ; Ruether BA; Pilarski LM
    Scand J Immunol; 1992 Dec; 36(6):843-53. PubMed ID: 1281335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective inhibition of IgE versus beta 2-microglobulin in human U-266 myeloma cell line treated with T-cell-derived factors.
    Rossi P; Galli E; Gidlund M; Salahuddin Z; Laan K; Wigzell H
    Scand J Immunol; 1985 Jul; 22(1):33-9. PubMed ID: 3895398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant translational control of the c-myc gene in multiple myeloma.
    Paulin FE; West MJ; Sullivan NF; Whitney RL; Lyne L; Willis AE
    Oncogene; 1996 Aug; 13(3):505-13. PubMed ID: 8760292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Size and charge heterogeneity of murine IgG-binding factors (IgG-BF).
    Blank U; Fridman WH; Daëron M; Galinha A; Moncuit J; Néauport-Sautès C
    J Immunol; 1986 Apr; 136(8):2975-82. PubMed ID: 3514751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
    Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
    Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.